Contribute Information
Can you contribute information about this project?
Contact the EWS Team
According to the Bank’s website, IFC has partnered with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. under an Upstream Engagement Letter to support the company's planned expansion in Asia, with a focus on aligning the company's investment plans with national healthcare priorities in target markets and strengthening local manufacturing and supply chains.
The proposed IFC advisory project aims to support Shanghai Fosun Pharmaceutical (Group) Co., Ltd.’s international expansion into Asia, with a strong focus on Southeast Asia. Through targeted market research, regulatory assessment, partner identification, and stakeholder engagement, the initiative will help the company address key challenges in scaling manufacturing, navigating complex regulatory environments, and building reliable local partnerships, laying the groundwork for investment in regional health systems across the target markets.
Estimated Total Budget: $61,552.00 (Project budget includes all project-funded activities)
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is a manufacturer of pharmaceutical products and medical devices in China. Fosun Pharma has been listed on the Shanghai Stock Exchange since 1998 and Hong Kong Stock Exchange since 2012.
| Private Actor 1 | Private Actor 1 Role | Private Actor 1 Sector | Relation | Private Actor 2 | Private Actor 2 Role | Private Actor 2 Sector |
|---|---|---|---|---|---|---|
| - | - | - | - | Shanghai Fosun Pharmaceutical (Group) Co. Ltd. | Client | - |
No contacts available at the time of disclosure.
ACCESS TO INFORMATION
You can submit a request for information disclosure at: https://disclosures.ifc.org/#/inquiries
If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.
ACCOUNTABILITY MECHANISM OF IFC/MIGA
The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org